Compare Ascendis Pharma A/S (ASND) vs Uber Technologies Inc (UBER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Uber Technologies Inc — how do they compare? Ascendis Pharma A/S trades at $263.68 (market cap $17.74B), while Uber Technologies Inc trades at $75.36 (market cap $151.73B). The key difference: Uber Technologies Inc is far larger — about 8.6× Ascendis Pharma A/S's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Uber Technologies Inc nearer its low. Which is the better fit depends on your goals.
| ASND | UBER | |
|---|---|---|
Market Cap | $17.74B | $151.73B |
Sector | Health | Industrials |
52-Week High | $277.18 | $100.10 |
52-Week Low | $163.32 | $68.61 |
Enterprise Value | $18.11B | $158.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Uber Technologies (UBER) trades at $74.54, showing modest daily gains of 0.26%. The stock maintains strong bullish technical momentum with positive moving average signals and trades near pivot point resistance at $75. Fundamentally, Uber demonstrates robust revenue growth from $31.9B in 2022 to $52.0B in 2025, with net income turning positive since 2023 and reaching $10.05B in 2025. Recent developments include strategic moves into autonomous vehicles with robotaxi pilots in Madrid and Munich.
Uber presents a compelling growth story with expanding profitability and dominant market position. The 81.7% analyst buy rating and $109.25 consensus price target suggest 46% upside potential. Key risks include execution challenges in autonomous vehicle expansion, competitive pressures in key markets like India, and potential margin compression as revenue growth moderates. The negative projected net cash flow for 2026 warrants monitoring of capital allocation strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Uber Technologies Inc
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →
